Subscribe
shutterstock_1940448004_hjbc
HJBC / Shutterstock.com
21 February 2023Big PharmaLiz Hockley

Sanofi backed by big pharma and more in SCOTUS clash

Case focuses on the enablement scope of patents | Amici curiae argue Amgen patents are too broad | Pfizer | Eli Lilly | AstraZeneca | Sanofi | Genentech | Bayer | Gilead Sciences| Johnson & Johnson.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Amgen v Sanofi: Big Pharma awaits SCOTUS decision
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Amgen v Sanofi: Big Pharma awaits SCOTUS decision
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Amgen v Sanofi: Big Pharma awaits SCOTUS decision
15 December 2022   As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court